SYDNEY, Australia, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced results of RECCE ® ...
Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® ...
Phase I/II study is tracking to meet primary endpoints RECCE ® 327 at 3,000mg over 15 minutes marks the fastest infusion rate of a high concentration Cohort fully recruited with remaining subjects to ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Hosted on MSN
Recce Pharmaceuticals secures A$85 million R&D tax incentive for global anti-infective programs
Recce Pharmaceuticals Ltd. ( (AU:RCE)) has shared an update. Recce Pharmaceuticals has been awarded an Advanced Overseas Finding for up to A$85 million by the Australian Government, which extends the ...
Phase 1/2 trial of RECCE ® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical Research Study will assess the ...
This new patent strengthens Recce’s intellectual property footprint across Asia, supporting its strategy to access high-growth ASEAN markets. The patent claims cover Recce Pharmaceuticals (ASX:RCE) ...
Recce Pharmaceuticals Ltd. (AU:RCE) has released an update. Recce Pharmaceuticals is set to begin a pivotal Phase 3 clinical trial in Indonesia for their RECCE 327 topical gel, targeting diabetic foot ...
China's consumer prices rose more slowly in October, while producer price deflation deepened, even as Beijing doubled down on stimulus policies to prop up its sputtering economy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback